Abstract
We studied cardioprotective as well as Akt and extracellular signal-activated kinase (ERK) activating effect of a Ca2+ antagonist and a beta-adrenergic receptor blocker during ischemia-reperfusion, and compared these properties of the substances with that of a poly(ADP-ribose) polymerase (PARP) inhibitor used as a positive control throughout the experiments. Langendorff-perfused isolated rat hearts were subjected to 25 min global ischemia followed by 45 min reperfusion, and recovery of energy metabolism as well as functional cardiac parameters were monitored. Although to varying extents, all substances improved recovery of creatine phosphate, ATP, intracellular pH, and reutilization of inorganic phosphate. These favorable changes were accompanied by improved recovery of heart function parameters and reduced infarct size. In addition and again to varying extents, all studied substances decreased oxidative damage (lipid peroxidation and protein oxidation), and activated Akt, glycogen synthase kinase (GSK)-3β, and ERK1/2. Correlation between cardioprotective and kinase activating effectivity of the compounds proved to be statistically significant. Physiological significance of these kinase activations was established by demonstrating that inhibition of Akt by LY294002 and ERK1/2 by PD98059 compromised the cardioprotective effect of all the substances studied. In conclusion, we demonstrated for the first time that activation of phosphatidylinositol-3-kinase (PI-3K)-Akt and ERK2 pathways significantly contributed to cardioprotective effects of a Ca2+ antagonist and a β-adrenergic receptor blocker. Furthermore, we found a strong correlation between cardioprotective and kinase-activating potencies of the substances studied (Verapamil, Metoprolol and two PARP inhibitors), which indicated the potentiality of these kinases as drug-targets in the therapy of ischemic heart disease.
Similar content being viewed by others
References
Zima AV, Blatter LA (2006) Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 71(2):310–321. doi:10.1016/j.cardiores.2006.02.019
Xia Y, Khatchikian G, Zweier JL (1996) Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart. J Biol Chem 271:10096–10102. doi:10.1074/jbc.271.19.11204
Rowe GT, Manson NH, Caplan M, Hess ML (1983) Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. Circ Res 53:584–591
Werner E (2004) GTPases and reactive oxygen species: switches for killing and signaling. J Cell Sci 117(Pt 2):143–153. doi:10.1242/jcs.00937
Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F Jr et al (2005) Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 280(42):35767–35775. doi:10.1074/jbc.M507075200
Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D et al (2005) Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 38(2):367–374. doi:10.1016/j.yjmcc.2004.12.001
Uchiyama T, Otani H, Okada T, Ninomiya H, Kido M, Imamura H et al (2002) Nitric oxide induces caspase-dependent apoptosis and necrosis in neonatal rat cardiomyocytes. J Mol Cell Cardiol 34(8):1049–1061. doi:10.1006/jmcc.2002.2045
Szabo C (2005) Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol Res 52(1):34–43. doi:10.1016/j.phrs.2005.02.017
de la Lastra CA, Villegas I, Sanchez-Fidalgo S (2007) Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 13(8):933–962. doi:10.2174/138161207780414241
Palfi A, Toth A, Kulcsar G, Hanto K, Deres P, Bartha E et al (2005) The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J Pharmacol Exp Ther 315(1):273–282. doi:10.1124/jpet.105.088336
Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G et al (2003) Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 65:1373–1382. doi:10.1016/S0006-2952(03)00077-7
Veres B, Radnai B, Gallyas F Jr, Varbiro G, Berente Z, Osz E et al (2004) Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 310(1):247–255. doi:10.1124/jpet.104.065151
Kovacs K, Toth A, Deres P, Kalai T, Hideg K, Gallyas F Jr et al (2006) Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol 71:441–452. doi:10.1016/j.bcp.2005.05.036
Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W et al (2000) Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation 102:2873–2879
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318–1321. doi:10.1126/science.282.5392.1318
Scheid MP, Woodgett JR (2001) PKB/Akt: functional insight from genetic models. Natl Rev 2:760–768
Romashkova JA, Makarov SS (1999) NF-κB is a target of Akt in antiapoptotic PDGF signaling. Nature 401:86–89. doi:10.1038/43474
Dimmeler S, Fleming I, Fisslthalter B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase by Akt dependent phosphorylation. Nature 399:601–605. doi:10.1038/21224
Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA et al (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497–1502. doi:10.1161/01.CIR.0000012529.00367.0F
Halmosi R, Berente Z, Osz E, Toth K, Literati-Nagy P, Sumegi B (2001) Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cardiac injury and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 59:1497–1505
Deres P, Halmosi R, Toth A, Kovacs K, Palfi A, Habon T et al (2005) Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J Cardiovasc Pharmacol 45(1):36–43. doi:10.1097/00005344-200501000-00007
Szabados E, Fischer GM, Gallyas F Jr, Kispal G, Sumegi B (1999) Enhanced ADP-ribosilation and its diminution by lipoamide following ischemia-reperfusion in perfused rat heart. Free Radic Biol Med 27(9/10):1103–1113. doi:10.1016/S0891-5849(99)00151-3
Toth A, Halmosi R, Kovacs K, Deres P, Kalai T, Hideg K et al (2003) Akt activation induced by an antioxidant compound during ischemia-reperfusion. Free Radic Biol Med 35:1051–1063. doi:10.1016/S0891-5849(03)00467-2
Lee S-R, Yang K-S, Kwon J, Lee C, Jeong W, Rhee SG (2002) Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 23:20336–20342. doi:10.1074/jbc.M111899200
Dauterman K, Topol E (2002) Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. Ann Med 34(7–8):514–522. doi:10.1080/078538902321117724
Mehta JL (1994) Emerging options in the management of myocardial ischemia. Am J Cardiol 73(3):18A–27A. doi:10.1016/0002-9149(94)90270-4
Buser PT, Wagner S, Wu ST, Derugin N, Parmley WW, Higgins CB et al (1989) Verapamil preserves myocardial performance and energy metabolism in left ventricular hypertrophy following ischemia and reperfusion. Phosphorus 31 magnetic resonance spectroscopy study. Circulation 80(6):1837–1845
Wolfe CL, Donnely TJ, Sievers R, Parmley WW (1991) Myocardial protection with verapamil during ischaemia and reperfusion: dissociation between myocardial salvage and the degree of ATP depletion during ischaemia. Cardiovasc Res 25(2):101–109. doi:10.1093/cvr/25.2.101
Farkas A, Qureshi A, Curtis M (1999) Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. Br J Pharmacol 128:41–50. doi:10.1038/sj.bjp.0702778
Markiewicz W, Wu SS, Sievers R, Parmley WW, Watters TA, James TL et al (1988) Beneficial effects of verapamil during metabolic acidosis in isolated perfused rat hearts. Cardiovasc Drugs Ther 1(5):493–502. doi:10.1007/BF02125732
Kalaycioglu S, Sinci V, Imren Y, Öz E (1999) Metoprolol prevents ischemia-reperfusion injury by reducing lipid peroxidation. Jpn Circ J 63:718–721. doi:10.1253/jcj.63.718
Bradley L, Doggrell SA (1984) Effects of the (+/−)-, (+)- and (−)-forms of propranolol, timolol and metoprolol on noradrenergic transmission in the rat isolated right ventricle. Arch Int Pharmacodyn Ther 270(1):61–78
Communal C, Colucci WS (2005) The control of cardiomyocyte apoptosis via the beta-adrenergic signaling pathways. Arch Mal Coeur Vaiss 98(3):236–241
Zhou H, Li XM, Meinkoth J, Pittman RN (2000) Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483–494. doi:10.1083/jcb.151.3.483
Crossthwaite AJ, Hasan S, Williams RJ (2002) Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J Neurochem 80(1):24–35. doi:10.1046/j.0022-3042.2001.00637.x
Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279(39):40419–40430. doi:10.1074/jbc.M405079200
Goto S, Xue R, Sugo N, Sawada M, Blizzard KK, Poitras MF et al (2002) Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 33(4):1101–1106. doi:10.1161/01.STR.0000014203.65693.1E
DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483–510. doi:10.1146/annurev.physiol.69.022405.154749
Povsic TJ, Kohout TA, Lefkowitz RJ (2003) Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278(51):51334–51339. doi:10.1074/jbc.M309968200
Raju RV, Kakkar R, Radhi JM, Sharma RK (1997) Biological significance of phosphorylation and myristoylation in the regulation of cardiac muscle proteins. Mol Cell Biochem 176(1–2):135–143. doi:10.1023/A:1006891302017
Abdel-Latif AA (2001) Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases, and contraction in smooth muscle. Exp Biol Med (Maywood) 226(3):153–163
Nadif Kasri N, Bultynck G, Sienaert I, Callewaert G, Erneux C, Missiaen L, Parys JB, De Smedt H (2002) The role of calmodulin for inositol 1, 4, 5-trisphosphate receptor function. Biochim Biophys Acta 1600(1–2):19–31
Acknowledgements
We thank Laszlo Giran and Bertalan Horvath for their excellent technical help. This work was supported by Hungarian Scientific Research Fund (OTKA) K-73738 and Ministry of Health and Welfare ETT 531/2006.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kovacs, K., Hanto, K., Bognar, Z. et al. Prevalent role of Akt and ERK activation in cardioprotective effect of Ca2+ channel- and beta-adrenergic receptor blockers. Mol Cell Biochem 321, 155–164 (2009). https://doi.org/10.1007/s11010-008-9929-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-008-9929-8